CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 160 enrolled
Drug / intervention
Testosterone gel (FE 999303)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02149264
NCT02149264Phase 3Completed
CompareCT.gov

A Phase 3, Open-Label, Non-Randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males

Ferring Pharmaceuticals·interventional·Posted May 29, 2014·Updated Oct 26, 2017

In Brief

A Phase 3 clinical trial evaluating Testosterone gel (FE 999303) for Adult Male Hypogonadism. Completed, enrolled 160 participants across 22 sites.

Detailed Summary

This is a phase 3, open-label, non-randomized, clinical trial to evaluate the efficacy and safety of FE 999303 (Testosterone gel) in adult hypogonadal males.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Male Hypogonadism
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 29, 2014
Enrollment StartJul 1, 2014
Primary CompletionMay 1, 2015
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.1 years ago

Interventions

Testosterone gel (FE 999303)drug